CAS: 79094-20-5; Daltroban

该化合物是一个化学化合物,主要作为选择性的色波体A2受体对立体体,以其在心血管研究和潜在治疗应用中的作用著称,特别是在与板块聚集和血管功能有关的条件下.Daltroban对波本体受体表现出高度的亲近性,这些受体参与了各种生理过程,包括血管抑制和板块激活.该化合物经常被研究其对血压调节的影响及其减轻血栓事件的潜力.就其化学结构而言,Daltroban具有有助于其受体特性的特定功能组别.和许多药剂一样,其功效和安全性是通过临床前科研究来评价,以确定其治疗潜力和任何相关的副作用.总的来说,Daltroban在医学化学领域,特别是心血管健康领域,具有重大的兴趣.

结构式图片

欧盟法规

ECHA物质C&L通报

上下游产品

CAS号98-60-2 对氯苯磺酰氯

合成工艺路线路线简述

  • 98-60-2 + 99075-24-8 = 79094-20-5 [标题:Reaction Conditions
    标题:Thromboxane A2 Receptor Antagonists. Synthesis And Activities Of Phenylsulfonamido Derivatives
    作者:Mais,D. E.; Mohamadi,F.; Dube,G. P.; Kurtz,W. L.; Brune,K. A.; Et Al
    参考文献:European Journal Of Medicinal Chemistry 日期:1991 卷标:26(8) 页码:821-7
📜以93的收率获得产物达尔卓潘
参考文献:Sulphonamidophenylcarboxylic Acid Compounds And Pharmaceutical
标题:Sulphonamidophenylcarboxylic Acid Compounds And Pharmaceutical
摘要:该发明提供了公式为##str1##的磺胺类化合物,其中r是氢原子或低级烷基基团;r.Sub.1是烷基,芳基,芳基烷基或芳基烯基,其中芳基基团在每种情况下均可以选择地被羟基,卤素,三氟甲基,低级烷基或烷氧基,或酰基,羧基或烷氧羰基取代一次或多次;n为1,2或3;w为一个价键或二价脂肪族碳链,并且该化合物的生理上可接受的盐,酯和酰胺.这些化合物具有出色的药理降脂活性和抑制血小板聚集的作用.

海关参考信息

专利信息


专利号:US-10925977-B2
优先权日:2006-10-05
标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

专利号:US-2003050305-A1
优先权日:2000-05-22
标题:Thromboxane inhibitors, compositions and methods of use
发明人:TEJADA INIGO SAENZ DE
摘要:The present invention describes methods for treating or preventing sexual dysfunctions in males and females, and for enhancing sexual responses in males and females by administering a therapeutically effective amount of at least one thromboxane inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one vasoactive agent. The male or female may preferably be diabetic. The present invention also provides novel compositions comprising at least one thromboxane inhibitor, and, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and, optionally, at least one therapeutic agent, such as, vasoactive agents, nonsteroidal antiinflanmmatory compounds (NSAIDs), selective cyclooxygenase-2 (COX-2) inhibitors, anticoagulants, angiotensin converting enzymes (ACE) inhibitors, angiotensin II receptor antagonists, renin inhibitors, and mixtures thereof. The present invention also provides methods for treating or preventing ischemic heart disorders, myocardial infarction, angina pectoris, stroke, migraine, cerebral hemorrhage, cardiac fatalities, transient ischaemic attacks, complications following organ transplants, coronary artery bypasses, angioplasty, endarterectomy, atherosclerosis, pulmonary embolism, bronchial asthma, bronchitis, pneumonia, circulatory shock of various organs, nephritis, graft rejection, cancerous metastases, pregnancy-induced hypertension, preeclampsia, eclampsia, thrombotic and thromboembolic disorders, intrauterine growth, gastrointestinal disorders, renal diseases and disorders, disorders resulting from elevated uric acid levels and dysmenorrhea, and for inhibiting platelet aggregation or platelet adhesion or relaxing smooth muscles.

专利号:US-10814013-B2
优先权日:2006-10-05
标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

专利号:AU-2007308022-A2
优先权日:2006-10-05
标题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

专利号:AU-2007308022-A1
优先权日:2006-10-05
标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

专利号:US-2008107598-A1
优先权日:2006-10-05
标 题:Efficient Synthesis of Chelators for Nuclear Imaging and Radiotherapy: Compositions and Applications

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Brantl SA, Khandoga AL, Siess W. Mechanism of platelet activation induced by endocannabinoids in blood and plasma. Platelets. 2014;25(3):151-61. doi: 10.3109/09537104.2013.803530. Epub 2013 Jun 21. doi: 10.1111/j.1748-1716.2012.02437.x. Epub 2012 May 4. doi: 10.1152/ajpheart.00403.2011. Epub 2011 Aug 19.
4: Malinowska B, Zakrzeska A, Kurz CM, Göthert M, Kwolek G, Wielgat P, Braszko JJ, Schlicker E. Involvement of central beta2-adrenergic, NMDA and thromboxane A2 receptors in the pressor effect of anandamide in rats. Naunyn Schmiedebergs Arch Pharmacol. 2010 Apr;381(4):349-60. doi: 10.1007/s00210-010-0497-6. Epub 2010 Mar 3. Epub 2005 Jul 25. Epub 2003 Aug 4.

合成参考文献


参考文献:10.1002/hep.510300229
摘要:Schieferdecker HL, Pestel S, Püschel GP, Götze O, Jungermann K. Increase by anaphylatoxin C5a of glucose output in perfused rat liver via prostanoids derived from nonparenchymal cells: direct action of prostaglandins and indirect action of thromboxane A(2) on hepatocytes. Hepatology. 1999 Aug;30(2):454–61. doi: 10.1002/hep.510300229.
参考文献:10.1016/0014-2999(92)90108-g
摘要:Sirois MG, Filep JG, Rousseau A, Fournier A, Plante GE, Sirois P. Endothelin-1 enhances vascular permeability in conscious rats: role of thromboxane A2. Eur J Pharmacol. 1992 Apr 22;214(2-3):119–25. doi: 10.1016/0014-2999(92)90108-g.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知